Arbutus Biopharma ((ABUS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arbutus Biopharma is conducting a study titled ‘A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.’ The study aims to assess the safety and tolerability of AB-101, a potential treatment for chronic hepatitis B (CHB), marking a significant step in addressing this chronic infection.
The intervention being tested is AB-101, an oral PD-L1 checkpoint inhibitor designed to treat chronic HBV infection, potentially in combination with other agents. The study also involves a placebo and nucleos(t)ide analogues, the latter being a standard treatment for CHB.
This Phase 1 study is interventional, with a randomized allocation and a parallel intervention model. It employs single masking, where participants are unaware of whether they receive the treatment or placebo. The primary purpose is treatment-focused, aiming to evaluate the drug’s effects in both healthy and CHB subjects.
The study began on August 30, 2023, and is currently active but not recruiting. The last update was submitted on July 16, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s timeline and potential market entry.
The study’s progress could influence Arbutus Biopharma’s stock performance, as successful results may boost investor confidence and market positioning. The development of AB-101 could impact the competitive landscape, particularly in the treatment of chronic HBV, where effective new therapies are in demand.
The study is ongoing, with further details available on the ClinicalTrials portal.